AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05232123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral product formulated in MCT (medium chain triglyceride) oil
Trial: NCT05169021
Drug: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Trial: NCT05169021
Drug: Amlodipine folic acid 5.8mg+standard antihypertensive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Trial: NCT04772443
Drug: DWJ1506
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWJ1506
Trial: NCT04772443
Drug: DWJ1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWJ1507
Trial: NCT04772443
Drug: DWC202011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWC202011
Trial: NCT04772443
Drug: DWJ1177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWC202011
Trial: NCT05764317
Drug: Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg
RxNorm normalized name: amlodipine / perindopril arginine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
Trial: NCT05764317
Drug: Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg
RxNorm normalized name: amlodipine / perindopril arginine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
Trial: NCT05764317
Drug: Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg
RxNorm normalized name: amlodipine / perindopril arginine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
Trial: NCT04465760
Drug: Xisomab 3G3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV or via catheter
Trial: NCT06132919
Drug: MC2-25 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT06132919
Drug: MC2-25 vehicle
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT01408069
Drug: MIGRANE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
Trial: NCT01408069
Drug: PARCEL
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
Trial: NCT04905147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug 15 mg
Trial: NCT06201065
Drug: oxaliplatin , fluorouracil, and leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-HAIC
Trial: NCT01351038
Drug: Epirubicine, Oxaliplatin, Capecitabine, Panitumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
Trial: NCT04674670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
Trial: NCT05102903
Drug: BR1016B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Trial: NCT06359899
Drug: AK0901 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral
Trial: NCT06359899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
Trial: NCT04834206
Drug: Docetaxel, nedaplatin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
Trial: NCT06585540
Drug: Placebo Preventative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive placebo (Normal Saline) while under general anesthesia
Trial: NCT06585540
Drug: Placebo Treatment
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this Arm will receive placebo as first line treatment of Post-Operative Nausea and Vomiting in the Post Anesthesia Care Unit
Trial: NCT05105256
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
Trial: NCT04958187
Drug: ANG-3777
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm assigned to this intervention will receive 2 mg/kg, IV
Trial: NCT06128148
Drug: JYP0322 50 mg qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
Trial: NCT06128148
Drug: JYP0322 100 mg qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
Trial: NCT06128148
Drug: JYP0322 200 mg qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
Trial: NCT06128148
Drug: JYP0322 100 mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
Trial: NCT06128148
Drug: JYP0322 150 mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
Trial: NCT06128148
Drug: JYP0322 200 mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
Trial: NCT01047072
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT04745351
Drug: RDV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as IV saline once daily
Trial: NCT04745351
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Treatment for COVID-19 Infection
Trial: NCT04771611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Looks exactly like the study drug, but it contains no active ingredient . Oral for four days (days 0,1 and days 8,9)
Trial: NCT05037162
Drug: Treatment administration (twice a day)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)
Trial: NCT06393634
Drug: Testosterone injection
RxNorm normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single injection of testosterone
Trial: NCT06393634
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A daily dose of testosterone gel
Trial: NCT06393634
Drug: Testosterone Oral
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A twice-daily pill of testosterone pill to swallow
Trial: NCT06224595
Drug: CS32582 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive CS32582 orally single or multiple doses
Trial: NCT06224595
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive placebo matching CS32582 orally single or multiple doses
Trial: NCT05360966
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Trial: NCT05127369
Drug: fluoxetine hydrochloride capsule
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluoxetine hydrochloride capsule
Trial: NCT06531161
Drug: Suxiao Jiuxin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxiao Jiuxin Pill is a traditional Chinese medicine compound composed of Ligusticum Wallichii and Borneo Camphorwood, and its clinical safety has been confirmed. Traditional Chinese medicine theory believes that Suxiao Jiuxin Pill has the effects of promoting qi and blood circulation, removing blood stasis and relieving pain, which may help alleviate symptoms of AMS.
Trial: NCT05192512
Drug: TQB2928 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2928 injection is a CD47 Blocker.
Trial: NCT05997524
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 was given orally twice daily on days 1-14 followed by a 7-day rest interval.
Trial: NCT05049278
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Continuous drug: norepinephrine 4mg \* 1@ + D5W 200 mL (20 μg/mL)~* Range: 0.03 \~ 0.09 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)
Trial: NCT05737563
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1600 mg/m2/d, oral, 2 weeks on and 1 week off.
Trial: NCT05378737
Drug: BAT8006 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
Trial: NCT04920383
Drug: ALPN-202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various doses
Trial: NCT04744662
Drug: ONL1204 Ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation administered by intravitreal (IVT) injection
Trial: NCT05813561
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 40mg
Trial: NCT04630353
Drug: HB-201 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB-201 given IV, one (1) time, on day 1.
Trial: NCT04630353
Drug: HB-201 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
Trial: NCT05950906
Drug: PDM608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDM608 subcutaneous at single or multiple dose(s) assigned by cohort
Trial: NCT05950906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.
Trial: NCT04704050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
Trial: NCT06270511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an oral suspension.
Trial: NCT05205941
Drug: MMV688533
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not exceeding 200mg
Trial: NCT05033041
Drug: Study drug placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of placebo (sterile normal saline)
Trial: NCT05384262
Drug: AZD0780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AZD0780 orally as a single ascending dose.
Trial: NCT03252626
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ml normal saline injection added into 10ml 0.9% saline.
Trial: NCT05168644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
Trial: NCT05384262
Drug: AZD0780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AZD0780 orally as a multiple ascending dose.
Trial: NCT05384262
Drug: AZD0780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AZD0780 orally as a single and multiple ascending dose.
Trial: NCT05384262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
Trial: NCT05384262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
Trial: NCT05384262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
Trial: NCT05384262
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive rosuvastatin orally.
Trial: NCT06018428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of placebo
Trial: NCT04745728
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-2mg/kg/d p.o. with a target accumulated dose of 12g.
Trial: NCT05429840
Drug: MT1980
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT05429840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT05124899
Drug: CAP UnScented
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen lip balm.
Trial: NCT05124899
Drug: CAP Mountain Berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen lip balm.
Trial: NCT04683575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral medication
Trial: NCT05283486
Drug: MYMD-1 600MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: 600mg drug
Trial: NCT05283486
Drug: MYMD-1 750mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: 750mg drug
Trial: NCT05283486
Drug: MYMD-1 900mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3: 900mg drug
Trial: NCT05283486
Drug: MYMD-1 1050mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 4: 1050mg drug
Trial: NCT05283486
Drug: placebo 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: 600mg placebo
Trial: NCT05283486
Drug: placebo 750mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: 750mg placebo
Trial: NCT05283486
Drug: placebo 900mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3: 900mg placebo
Trial: NCT06188260
Drug: Systane COMPLETE Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant
Trial: NCT05577962
Drug: T group
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
Trial: NCT05194007
Drug: Frondanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
Trial: NCT05194007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
Trial: NCT00533741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline for injection.
Trial: NCT05975996
Drug: Cyclophosphamide added to standard immunosuppressive therapy with herombopag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
Trial: NCT04186299
Drug: Articaine Hydrochloride + Epinephrine
RxNorm normalized name: articaine hydrochloride / epinephrine Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
Trial: NCT00093171
Drug: rFIX
RxNorm normalized name: rFIXFc
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06065774
Drug: The Laterally Closed Tunnel Technique with collagen matrix mucograft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene.
Trial: NCT04683640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral Placebo for 4 weeks
Trial: NCT05478109
Drug: [14C]XZP-3287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg suspension containing 50µCi of \[14C\] XZP-3287
Trial: NCT06611514
Drug: Prasterone (DHEA)
RxNorm normalized name: prasterone (DHEA)
DrugBank: Prasterone sulfate (DB05804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prasterone 6.5 mg vaginal tablets
Trial: NCT04975438
Drug: GSK1070806
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1070806 will be administered
Trial: NCT04975438
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered
Trial: NCT06137469
Drug: Acetaminophen/SHR20004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR20004 was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
Trial: NCT06137469
Drug: Acetaminophen/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.